Adverum Biotechnologies appoints Amber Salzman as CEO
Mr. Cleveland was appointed Adverum’s Executive Chairman in October 2016 after serving as the company’s CEO and a Director since December 2015.
He was chief executive officer of Celladon Corporation, and he brings more than 20 years of leadership experience to Adverum, including management and operational experience across the biotechnology industry.
This includes positions at multiple public biotechnology companies, including chief executive officer, president, chief financial officer and board member as well as chief operating officer at a venture capital firm.
Mr. Cleveland received his BA from Washington University in St. Louis and his JD from the Northwestern University School of Law.
Amber Salzman, formerly president and COO, has been appointed CEO.
Dr. Salzman joined Adverum as President and Chief Operating Officer in 2016 after the combination of Annapurna Therapeutics with Avalanche Biotechnologies. She served as co-founder, president and Chief Executive Officer of Annapurna Therapeutics prior to the combination.
Prior to Annapurna, Dr. Salzman served in leadership roles in large pharmaceutical companies, small pharmaceutical companies, and in the rare disease community including her role as chief executive officer of Cardiokine rior to its acquisition by Cornerstone Therapeuticsc.
Previously, Dr. Salzman served as a member of the GlaxoSmtihKline’s R&D executive team. She has led initiatives to accelerate drug development and moderate costs, and established a Development Support Center in India.
Dr. Salzman received her B.A. from Temple University and her Ph.D. from Bryn Mawr College. ■